Vaccine 411 - tracking the race to find a vaccine for the Coronavirus Covid 19

Vaccine 411 061620

This is Vaccine 4-1-1.  As the race for a COVID-19 vaccine continues, here are the numbers:

143 vaccines are in development, according to The New York Times  

125 are in pre-clinical trials. 

8 are in Phase 1 Clinical Trials.

8 are in Phase 2.

2 are in Phase 3. One in the United Kingdom and one in Australia.

On this episode of Vaccine 411… researchers in Australia hope to re-purpose a tuberculosis vaccine developed in the 1900’s to fight today’s COVID-19. 

First, the news: The FDA has revoked their emergency use authorization for Chloroquine and Hydroxychloroquine to treat COVID-19. Beijing based, Sinovac Biotech, announced their vaccine candidate “CoronaVac” was safe in humans and induced antibodies in more than 90% of candidates. According to statnews.com, they are submitting a design protocol to move to Phase III, that will involve candidates in China and Brazil. Europe’s Inclusive Vaccine Alliance, comprised of France, Germany, Italy and The Netherlands have signed an agreement with AstraZeneca to provide up to 400 million doses of the potential COVID-19 vaccine, reports Reuters. Germany will buy nearly 23% of CureVac, for 340 million dollars. CureVac is one of many companies working on a COVID-19 vaccine. They plan to begin Phase I human trials this month.  

See acast.com/privacy for privacy and opt-out information.